ASH2021注目テーマ「Late-Breaking Abstracts Session #6」

再発・難治性非ホジキンリンパ腫の2次治療において
tisa-celのEFSは標準治療と有意差なし：BELINDA試験 Tisagenlecleucel Vs Standard of Care As Second-Line Therapy of Primary Refractory or Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma: Analysis of the Phase Ⅲ Belinda Study (#LBA-6)

Michael R. Bishop（The David and Etta Jonas Center for Cellular Therapy, University of Chicago, IL）